Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HPN | P05981 | 3/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825856 | 0.80 | ALDH1A1 (0.51) | ALDH1A1TSHRCYP3A4HTTHSD17B10 | |
| SCHEMBL19441740 | 0.80 | ALDH1A1 (0.51) | ALDH1A1TSHRCYP3A4HTTHSD17B10 | |
| SCHEMBL5566978 | 0.79 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP3A4HTTHSD17B10 | |
| SCHEMBL30896660 | 0.75 | GAA (0.56) | ALDH1A1TSHRCYP3A4HTTGAA | |
| SCHEMBL17446911 | 0.75 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4HTTHSD17B10 | |
| SCHEMBL29952032 | 0.73 | ALDH1A1 (0.47) | ALDH1A1TSHRCYP3A4HTTHSD17B10 | |
| SCHEMBL5568022 | 0.72 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4HTTHSD17B10 | |
| SCHEMBL13041357 | 0.72 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4HTTHSD17B10 | |
| SCHEMBL5335059 | 0.72 | GAA (0.52) | ALDH1A1CYP3A4HTTGAAPOLB | |
| SCHEMBL15478776 | 0.72 | GAA (0.52) | ALDH1A1TSHRCYP3A4HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | BCL2, BAK1, BRD4 | ALDH1A1 4196/4885TSHR 4060/4885CYP3A4 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.